Pluristem - Single Platform for Unmet Medical Needs
Cell therapeutics is a field that faces numerous challenges in the current scenario of COVID-19 and other diseases, which is undergoing continuous advancements. Pluristem Therapeutics Inc. is a clinical-stage regenerative medicine firm that develops cell therapeutics for inflammation, muscular injuries, hematological illnesses, and radiation exposure using placental cells and a proprietary three-dimensional (3D) technology platform.
Pluristem plans to produce effective cell treatments that can be marketed to help patients who require novel therapeutic choices. They create “off-the-shelf” placenta-derived products that don’t need genetic or tissue matching before administration and may be used in nearly any therapeutic scenario. Pluristem makes unique cell products for several indications, and the company expects to have a pipeline of distinctive products and indications that will allow it to target big worldwide markets. They look for innovative ways to improve their clinical development programs while staying committed to existing corporate, academic, and government collaborations.
Placental grown (PLX) cells developed by Pluristem are placenta-derived, mesenchymal-like tenacious stromal cells that are enlarged ex vivo and may be given to patients without the necessity for tissue or genetic matching. These cells secrete soluble macromolecules like cytokines, chemokines, and growth factors that function in a paracrine and endocrine way to help injured tissue repair by activating the body’s regeneration mechanisms. Due to their ability to release components in response to chemical distress signals from regions damaged by muscular trauma or inflammation, PLX-PAD cells have regenerative potential. These therapeutic substances drive tissue regeneration, differentiation, and immune-mediated inflammatory control while also triggering the body’s healing systems. The immune system, which plays a crucial role in the body’s reaction to traumas, modulates PLX-PAD cells. YakyYanay CEO & President of Plursitem says, “In the last decade, we have developed an automated and robust current Good Manufacturing Practice (cGMP) manufacturing platform for allogeneic cells originating from the fetal and maternal cells from the placenta. Using this platform, we can produce large quantities of high-quality cells suitable for various applications and uses. The manufacturing platform enables us to develop targeted pipelines of cellular product candidates including induced or modified PLX cells.”
Tumor necrosis factor-alpha (TNF-a) and interferon-gamma (IFN-g) have been used to transiently modify the secretion profile of PLX-Immune cells developed by Pluristem. The product has been tested in preclinical tests. Peer-reviewed research published in the journal Scientific Reports, published by Nature, looked at the effect of the cells on over 50 different types of human malignant cells. The findings revealed that PLX-Immune cells inhibited the proliferation of 45 per cent of the cancer cell lines examined, with a substantial inhibitory impact on breast, colorectal, kidney, liver, lung, muscle, and skin cancer cell lines. PLX cells suppressed cancer cell lines with similar features, according to a comprehensive bioinformatics study.
This knowledge might be utilized in the future to screen patients’ tumors to select individuals who are most likely to respond to PLX cell therapy. Yanay adds, “Our talented management team and I asked this question in recent months as part of our five-year strategic discussions. The outcome is clear: Develop effective and innovative cellular product candidates while assuring manufacturing capacity on the back end when the product candidate is ready for market. We believe that this is our defining competitive advantage. Over the years, we have received interest from potential partners to use our platform for pharmaceuticals and other industries. Pluristem intends to use its unmatched technological advantage to establish mutually advantageous partnerships towards the best utilization and optimization of our assets for the benefit of our shareholders.”
The company also recently developed a state-of-the-art, proprietary bioreactor system which provides a three dimensional (3D) micro-environment for the cells that resembles the environment in the human body. As a result, the cells expand rapidly and remain healthy and potent as the team alter conditions within their bioreactors to transform them into unique, patented cell therapy products.Pluristem’s advanced manufacturing technology can generate cell products on a mass scale with batch-to-batch consistency, making them true commercial products.
Pluristem aims to create, manufacture, and distribute highly effective cell products that will treat people worldwide by leveraging superior technology and its position as a global leader in cell therapy.
“One platform with multiple applications targeting significant unmet medical needs.”